| answer text |
<p>Lariam (mefloquine), is an extremely effective antimalarial and is one of a number
of antimalarials for travellers currently recommended by the Advisory Committee on
Malaria Prevention (ACMP), an expert advisory committee of Public Health England (PHE)
established in 1998 to formulate evidence-based guidelines on malaria prevention in
the United Kingdom.</p><p> </p><p> </p><p> </p><p>The use of mefloquine, for travellers,
including military personnel, to high risk areas should be based on an individual
risk assessment that takes into consideration the destination of travel, planned activities
while travelling and the individual’s current health and medical history.</p><p> </p><p>
</p><p> </p><p>The ACMP regularly reviews data on safety and efficacy of all antimalarials.
Whenever new evidence about antimalarials appears the ACMP considers this as part
of its continuous process of developing advice.</p><p> </p><p> </p><p> </p><p>The
ACMP will be meeting in summer 2015 to finalise the 2015 revision of the ACMP guidelines.
This meeting will review current evidence on the use of mefloquine, including data
provided by Roche, and recommendations made by other countries including the United
States with regard to the use of mefloquine for malaria prevention.</p><p> </p>
|
|
